摘要:
The invention relates to novel silylated polyaryletherketones containing at least one unit with general structural formula (I) or (II). By incorporating bridging or non-bridging silyl groups into polyaryletherketones, it is possible to define or adjust the melting point or melting range of the polyaryletherketones more exactly than has hitherto been possible. Fine-tuning of the material properties of polyaryletherketones can be achieved in this manner.
摘要:
The present invention relates to a polymer comprising a cholane core having at least one derivatizable group covalently bonded thereto and a hydrophilic polymer chain covalently bonded to derivatizable group(s) and a process for producing it The present invention also relates to micellar aggregate formed from the polymer of the present.
摘要:
Electrolyte compositions in which a salt is disposed in a thiol-ene matrix. The compositions retain their shape under operating conditions and exhibit an ionic conductivity of at least 1x10-6 S/cm when measured in the absence of solvent at 25 °C.
摘要:
Provided is a hydrophilic polymer derivative having a benzylidene acetal linker whose hydrolysis rate at the pH of a weakly acidic environment in the living body can be accurately controlled. A hydrophilic polymer derivative having a benzylidene acetal linker, which is represented by the following formula (1):
wherein R 1 is a hydrogen atom or a hydrocarbon group; R 2 , R 3 , R 4 , R 5 , and R 6 are each independently a hydrogen atom or a substituent and at least one of R 3 , R 4 , and R 5 is an electron-withdrawing substituent or at least one of R 2 and R 6 represents a substituent; X 1 is a chemically reactive functional group; P is a hydrophilic polymer; w is an integer of 1 to 8; and Z 1 and Z 2 are an independently selected divalent spacer.
摘要:
Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein: i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is equal to 2 or greater than 2, preferably 3, 4, 5, 6, 7 or 8; ii) the second precursor molecule is of the general formula:
A-[(C 3 H 6 O) n -(C 2 H 4 O) m -B] i
wherein m and n are integers from 1 to 200 i is greater than 2, preferably 3, 4, 5, 6, 7 or 8 A is a branch point B is a conjugated unsaturated group.
摘要翻译:用于制备用作组织密封剂的生物材料的方法,包含用于形成生物材料的前体的试剂盒以及所得生物材料在本文中描述。 生物材料由包含至少第一和第二前体分子的组合物形成,其中:i)第一前体分子是具有选自硫醇或氨基的x个亲核基团的聚(乙二醇)基聚合物, 其中x等于2或大于2,优选3,4,5,6,7或8; ii)第二前体分子具有以下通式:ƒ€ƒ€ƒ€ƒ€ƒ€ƒA - [(C 3 H 6 O)n - (C 2 H 4 O)m -B ]其中m和n是1至200i的整数大于2,优选3,4,5,6,7或8 A是分支点B是共轭不饱和基团。
摘要:
Improved poly(amido ethylenimine) copolymers for gene delivery are disclosed. One illustrative embodiment includes polyethylene glycol (PEG) covalently bonded to a branched poly (triethyenetetramine/cystamine bisacrylamide) copolymer (poly (TETA/CBA) ). The polyethylene glycol can be linear or branched. Another illustrative embodiment includes an RGD peptide covalently bonded to the poly (TETA/CBA) -PEG conjugate. Still another illustrative embodiment includes a method of using these compositions for transfecting a cell with a nucleic acid.
摘要:
The present invention provides both crosslinked polymer compositions capable of forming hydrogels upon exposure to an aqueous environment and thiosulfonate hydrogel-forming components. The thiosulfonate hydrogel-forming components of the invention are preferably multi-arm thiosulfonate polymer derivatives that form a crosslinked polymer composition when exposed to a base without requiring the presence of a second cross-linking reagent, redox catalyst, or radiation. Methods for forming hydrogel compositions, as well as methods for using the hydrogels, are also provided.
摘要:
The invention provides novel water soluble pegylated esters of rapamycin, having general structure (I), wherein n is an integer from about 5 to about 450, as well as pharmaceutical compositions containing these compounds and methods for their use as immunosuppressive, anti-inflammatory, antifungal, antiproliferative and antitumor agents.